Automate Your Wheel Strategy on ARGX
With Tiblio's Option Bot, you can configure your own wheel strategy including ARGX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARGX
- Rev/Share 59.936
- Book/Share 99.8744
- PB 8.0986
- Debt/Equity 0.0071
- CurrentRatio 5.5953
- ROIC 0.0768
- MktCap 49473940978.0
- FreeCF/Share 7.7583
- PFCF 104.4802
- PE 35.9867
- Debt/Assets 0.006
- DivYield 0
- ROE 0.2366
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ARGX | Robert W. Baird | Outperform | Neutral | -- | $858 | Dec. 18, 2025 |
| Downgrade | ARGX | Wolfe Research | Outperform | Peer Perform | -- | -- | Nov. 24, 2025 |
| Resumed | ARGX | Truist | -- | Buy | -- | $918 | Sept. 15, 2025 |
| Downgrade | ARGX | Deutsche Bank | Buy | Hold | -- | -- | Sept. 11, 2025 |
| Initiation | ARGX | RBC Capital Mkts | -- | Outperform | -- | $850 | Aug. 25, 2025 |
| Upgrade | ARGX | Deutsche Bank | Hold | Buy | -- | -- | July 8, 2025 |
| Resumed | ARGX | Morgan Stanley | -- | Overweight | -- | $700 | July 3, 2025 |
| Upgrade | ARGX | Robert W. Baird | Neutral | Outperform | -- | $680 | May 13, 2025 |
| Upgrade | ARGX | Bernstein | Market Perform | Outperform | -- | -- | March 17, 2025 |
| Upgrade | ARGX | Deutsche Bank | Sell | Hold | -- | -- | March 12, 2025 |
News
KROS or ARGX: Which Is the Better Value Stock Right Now?
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
Read More
5 Top Stocks With High 2026 Earnings Growth Targets
Published: December 22, 2025 by: Seeking Alpha
Sentiment: Positive
The S&P 500 experienced sharp swings in 2025 due to shifts in trade policy, AI speculation, and rate cuts, while corporate profits remained resilient. Broader AI adoption and steady economic growth are expected to drive double-digit earnings growth in the S&P 500 in 2026. Tech is expected to dominate earnings growth again next year, but more sectors are projected to contribute.
Read More
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
Published: December 19, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Read More
KROS vs. ARGX: Which Stock Is the Better Value Option?
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
argenx: Sights Set On $1,000
Published: November 26, 2025 by: Seeking Alpha
Sentiment: Positive
argenx continues to outperform expectations, driven by Vyvgart's strong commercial momentum and impressive growth in CIDP and gMG markets. Vyvgart is on track to deliver more than $4.1 billion in net sales in 2025, and there are five late-stage readouts in 2025 that could further improve the long-term outlook. Profitability and robust cash generation add business development as another avenue for growth.
Read More
Baron Opportunity Fund Q3 2025 Portfolio Update
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
This quarter, we re-established a position in Arista Networks, a leading provider of high-performance networking solutions for data centers, cloud providers, and enterprises. We initiated a starter position in Synopsys after shares sold off following the company's third quarter earnings report and our in-person meeting with management. We exited our CyberArk Software Ltd. position after its acquisition by Palo Alto Networks was announced.
Read More
KROS vs. ARGX: Which Stock Is the Better Value Option?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two stocks is more attractive to value investors?
Read More
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
Published: October 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagnostic imaging services and related solutions in the U.S. Intuitive Surgical, Inc. manufactures the da Vinci Surgical System, a robotic surgical system used for minimally invasive surgical procedures.
Read More
INCY or ARGX: Which Is the Better Value Stock Right Now?
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
INCY vs. ARGX: Which Stock Is the Better Value Option?
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how argenex SE (ARGX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Read More
FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations
Published: September 18, 2025 by: Business Wire
Sentiment: Neutral
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a significant expansion of its global partnership with argenx SE, a global immunology company. As part of the expanded agreement, FUJIFILM Biotechnologies will initiate manufacturing of argenx' drug substance for efgartigimod at the Holly Springs, North Carolina, site in 2028. argenx is the first anno.
Read More
argenx SE - Special Call
Published: September 16, 2025 by: Seeking Alpha
Sentiment: Neutral
argenx SE - Special Call Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Roeland Vanhauwaert Peter Ulrichts - Chief Scientific Officer Luc Truyen - Chief Medical Officer Rebecca Shilling Jeff Guptill Tim Van Hauwermeiren - Co-Founder, CEO & Executive Director Conference Call Participants Steven Burden Ricardo Maselli Danielle Brill Bongero - Truist Securities, Inc., Research Division Yaron Werber - TD Cowen, Research Division Ricardo Maselli, M.D. Leland Gershell - Oppenheimer & Co. Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Patrick Culliton - Stifel, Nicolaus & Company, Incorporated, Research Division Maddalena …
Read More
Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
argenx SE (NASDAQ:ARGX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Karl Gubitz - Chief Financial Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning. Welcome to Morgan Stanley's Global Healthcare Conference.
Read More
KMDA or ARGX: Which Is the Better Value Stock Right Now?
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Kamada (KMDA) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
3 Healthcare Pathbreakers With Long-Term Tailwinds
Published: September 01, 2025 by: MarketBeat
Sentiment: Positive
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals and never achieve them.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
Published: August 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
argenx SE (ARGX) Q2 2025 Earnings Call Transcript
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Neutral
argenx SE (NASDAQ:ARGX ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Karen Massey - Chief Operating Officer Karl Gubitz - Chief Financial Officer Luc Truyen - Chief Medical Officer Timothy Van Hauwermeiren - Co-Founder, CEO & Executive Director Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Charles Pitman - Barclays Bank PLC, Research Division Derek Christian Archila - Wells Fargo Securities, LLC, Research Division Douglas Dylan Tsao - H.C. …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
Published: July 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
Published: July 07, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
EXEL or ARGX: Which Is the Better Value Stock Right Now?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
VYVGART ® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the largest study of CIDP patients to date First novel mechanism of action for CIDP treatment in more than 30 years June 20, 2025, 7:00 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the European Commission (EC) approved VYVGART® (efgartigimod alfa) 1000mg for subcutaneous (SC) injection as a …
Read More
EXEL or ARGX: Which Is the Better Value Stock Right Now?
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
June 3, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karl Gubitz, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 8:40 AM ET in Miami, FL.
Read More
About argenx SE (ARGX)
- IPO Date 2017-05-18
- Website https://www.argenx.com
- Industry Biotechnology
- CEO Timothy Van Hauwermeiren
- Employees 1599